Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Completed Phase 1 Trials for Alisertib (DB05220)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01897012Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasTreatment